PE20020601A1 - TIAZOLIDINADIONAS COMO AGONISTAS DE PPARy - Google Patents
TIAZOLIDINADIONAS COMO AGONISTAS DE PPARyInfo
- Publication number
- PE20020601A1 PE20020601A1 PE2001001256A PE2001001256A PE20020601A1 PE 20020601 A1 PE20020601 A1 PE 20020601A1 PE 2001001256 A PE2001001256 A PE 2001001256A PE 2001001256 A PE2001001256 A PE 2001001256A PE 20020601 A1 PE20020601 A1 PE 20020601A1
- Authority
- PE
- Peru
- Prior art keywords
- ppary
- adions
- thiazolidine
- agonists
- thiazolidinadiona
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIERE A UN METODO QUE COMPRENDE LA ADMINISTRACION DE UN AGONISTA DEL RECEPTOR ACTIVADO POR EL PROLIFERADOR DE PEROXISOMA (PPARy) DE FORMULA I SELECCIONADO DE 5-(4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]-BENCIL)-2,4-TIAZOLIDINADIONA, (+)-5-[[4-[(3,4-DIHIDRO-6-HIDROXI-2,5,7,8-TETRAMETIL-2H-1-BENZOPIRAN-2-IL)METOXI]FENIL]METIL-2,4-TIAZOLIDINADIONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL PARA LA ESTIMULACION DE CRECIMIENTO Y/O REPARACION DE NEURONAS EN ENFERMEDADES O PROCESOS CARACTERIZADOS POR DEGENERACION, LESION COMO APOPLEJIA, ALZHEIMER, DEMENCIAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0030845.2A GB0030845D0 (en) | 2000-12-18 | 2000-12-18 | Novel treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020601A1 true PE20020601A1 (es) | 2002-09-22 |
Family
ID=9905313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001001256A PE20020601A1 (es) | 2000-12-18 | 2001-12-14 | TIAZOLIDINADIONAS COMO AGONISTAS DE PPARy |
Country Status (15)
Country | Link |
---|---|
US (2) | US20040077525A1 (es) |
EP (2) | EP1345598B1 (es) |
JP (2) | JP2004518652A (es) |
AR (1) | AR032001A1 (es) |
AT (1) | ATE372118T1 (es) |
AU (1) | AU2002222180A1 (es) |
DE (1) | DE60130365T2 (es) |
DK (1) | DK1345598T3 (es) |
ES (1) | ES2292529T3 (es) |
GB (1) | GB0030845D0 (es) |
PE (1) | PE20020601A1 (es) |
PT (1) | PT1345598E (es) |
TW (1) | TWI298998B (es) |
UY (1) | UY27071A1 (es) |
WO (1) | WO2002049626A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050004179A1 (en) * | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
WO2005016339A1 (en) * | 2003-07-24 | 2005-02-24 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
NZ571871A (en) * | 2006-03-16 | 2011-07-29 | Metabolic Solutions Dev Co | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
WO2008036678A2 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
EP3053440B1 (en) * | 2007-04-11 | 2020-08-12 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
CN106692144A (zh) | 2009-03-11 | 2017-05-24 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
US20140235676A1 (en) * | 2011-10-13 | 2014-08-21 | Case Western Reserve University | Rxr agonist compounds and methods |
AU2013359903A1 (en) * | 2012-12-11 | 2015-07-02 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
US20150359849A1 (en) * | 2013-01-31 | 2015-12-17 | President And Fellows Of Harvard College | Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition |
US10034868B2 (en) | 2014-11-04 | 2018-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prevention and the treatment of rapidly progressive glomerulonephritis |
GB201805554D0 (en) * | 2018-04-04 | 2018-05-16 | Wren Therapeutics | Therapy for protein misfolding disease |
JP2021527061A (ja) * | 2018-06-06 | 2021-10-11 | ミノリックス セラピューティクス エセ.エレ. | 5−[[4−[2−[5−アセチルピリジン−2−イル]エトキシ]ベンジル]−1,3−チアゾリジン−2,4−ジオンおよびその塩の使用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741803A (en) * | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
JP4473355B2 (ja) * | 1997-11-19 | 2010-06-02 | 武田薬品工業株式会社 | アポトーシス抑制剤 |
EP1047423B1 (en) * | 1997-11-19 | 2006-05-10 | Takeda Pharmaceutical Company Limited | Novel apoptosis inhibitors |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
ATE476978T1 (de) * | 1998-12-17 | 2010-08-15 | Mindset Biopharmaceuticals Usa | Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns |
JP2000273040A (ja) * | 1999-01-19 | 2000-10-03 | Sankyo Co Ltd | トログリタゾンを含有するアポトーシス抑制剤 |
US6204288B1 (en) * | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
GB9908647D0 (en) * | 1999-04-15 | 1999-06-09 | Smithkline Beecham Plc | Novel compounds |
AU7995300A (en) * | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
-
2000
- 2000-12-18 GB GBGB0030845.2A patent/GB0030845D0/en not_active Ceased
-
2001
- 2001-12-12 EP EP01271216A patent/EP1345598B1/en not_active Expired - Lifetime
- 2001-12-12 DK DK01271216T patent/DK1345598T3/da active
- 2001-12-12 PT PT01271216T patent/PT1345598E/pt unknown
- 2001-12-12 ES ES01271216T patent/ES2292529T3/es not_active Expired - Lifetime
- 2001-12-12 US US10/450,885 patent/US20040077525A1/en not_active Abandoned
- 2001-12-12 AT AT01271216T patent/ATE372118T1/de not_active IP Right Cessation
- 2001-12-12 EP EP07115642A patent/EP1911446A3/en not_active Withdrawn
- 2001-12-12 JP JP2002550968A patent/JP2004518652A/ja active Pending
- 2001-12-12 WO PCT/GB2001/005488 patent/WO2002049626A2/en active IP Right Grant
- 2001-12-12 AU AU2002222180A patent/AU2002222180A1/en not_active Abandoned
- 2001-12-12 DE DE60130365T patent/DE60130365T2/de not_active Expired - Lifetime
- 2001-12-14 UY UY27071A patent/UY27071A1/es not_active Application Discontinuation
- 2001-12-14 PE PE2001001256A patent/PE20020601A1/es not_active Application Discontinuation
- 2001-12-17 TW TW090131174A patent/TWI298998B/zh not_active IP Right Cessation
- 2001-12-18 AR ARP010105872A patent/AR032001A1/es unknown
-
2007
- 2007-06-13 US US11/762,220 patent/US20070238757A1/en not_active Abandoned
-
2008
- 2008-06-05 JP JP2008148304A patent/JP2008260777A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1345598A2 (en) | 2003-09-24 |
UY27071A1 (es) | 2002-07-31 |
EP1911446A3 (en) | 2008-09-24 |
AR032001A1 (es) | 2003-10-22 |
WO2002049626A2 (en) | 2002-06-27 |
ES2292529T3 (es) | 2008-03-16 |
ATE372118T1 (de) | 2007-09-15 |
DK1345598T3 (da) | 2008-02-04 |
AU2002222180A1 (en) | 2002-07-01 |
EP1345598B1 (en) | 2007-09-05 |
WO2002049626A3 (en) | 2002-10-17 |
US20070238757A1 (en) | 2007-10-11 |
JP2008260777A (ja) | 2008-10-30 |
DE60130365T2 (de) | 2008-05-29 |
PT1345598E (pt) | 2007-12-06 |
TWI298998B (en) | 2008-07-21 |
EP1911446A2 (en) | 2008-04-16 |
JP2004518652A (ja) | 2004-06-24 |
DE60130365D1 (de) | 2007-10-18 |
US20040077525A1 (en) | 2004-04-22 |
GB0030845D0 (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020601A1 (es) | TIAZOLIDINADIONAS COMO AGONISTAS DE PPARy | |
PE20071184A1 (es) | Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo | |
AR057970A2 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones | |
CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
ES2192264T3 (es) | Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina. | |
UY30442A1 (es) | Composiciones farmaccuticas de ropinirol, mctodos de uso, proceso de preparacinn y aplicaciones. | |
BRPI0412054A (pt) | preparação farmacêutica transdérmica | |
PA8603201A1 (es) | Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas | |
AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos | |
PE20070813A1 (es) | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad | |
NO20075427L (no) | Ny farmasoytisk formulering inneholdende et biguanid og et tiazolidindionderivat | |
CL2008003789A1 (es) | Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer. | |
AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
MA29281B1 (fr) | Forme posologique orale au rosiglitazone | |
PE20090875A1 (es) | Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos | |
CY1106226T1 (el) | Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης | |
CY1105252T1 (el) | Το υδροχλωρικο αλας της 5-[4-[2-(ν-μεθυλο-ν-(2-πυριδυλο)αμινο)-αιθοξυ]βενζυλο]θειαζολιδινο-2,4-διονης | |
AR048948A1 (es) | Una composicion farmaceutica antimicobacteriana | |
CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
PE20030277A1 (es) | Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa | |
AR049302A1 (es) | Modulacion de receptores activados por proliferador de peroxisoma | |
AR045330A1 (es) | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla | |
PT1446404E (pt) | Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos | |
EA200300005A1 (ru) | Соль тиазолидиндиона для лечения сахарного диабета | |
UY28251A1 (es) | Uso del hidrocloruro de la base del principio activo 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2 (1h)- oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-pipperidin)-piperazina en combinación con sumatriptano para el tratamiento de la |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |